Atlas Trials

Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBC

Clinical trial NCT04819399 · UNKNOWN

Trial details

NCT number
NCT04819399
Sponsor
Lindis Biotech GmbH
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
Urinary Bladder Neoplasms
Start date
2020-07-07
Primary completion
2022-12-30
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.